SI Stock Forecast & Price Target

Shoulder Innovations is well positioned by its differentiated shoulder-focused portfolio, which combines high-performing implants, planning software, and an increasingly robust pipeline that is broadening its addressable market through new indications and enabling technologies. Q2 revenue of $17.2M rose 56% year over year, gross margin reached 78.3%, and management lifted FY26 revenue guidance to $67M-$69M, while surgeon additions and ASPs both continued to improve. The bullish outlook is further supported by a capital-light model with operating leverage potential, full commercial launches already contributing to ASP expansion, and a robotic offering slated for submission in 1H27 that could deepen adoption and strengthen long-term growth.

Shoulder Innovations is exposed to a fragile growth profile because its 2Q26 performance, while up 56.0% Y/Y to about $17.2 million, still relies heavily on procedure growth and surgeon adoption that can slow if a smaller number of new surgeons ramps more slowly than modeled. The outlook is negative because SG&A rose 5.6% above Street expectations, operating expenses are expected to consume a higher percentage of sales in 3Q26, and the company itself flags downside from higher spend, weaker shoulder market growth, and delayed entry into new market segments. In addition, FY26 guidance of roughly $67 million to $69 million depends on normal seasonality and a 4Q step-up even as ASPs are likely to fall in 4Q from procedure mix, pressuring margins and limiting earnings leverage.